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ABSTRACT 
Despite their low abundance, phosphoinositides are critical regulators of 
intracellular signaling and membrane compartmentalization. However, little is known of 
phosphoinositide function at the postsynaptic membrane. Here we show that continuous 
synthesis and availability of phosphatidylinositol-(3,4,5)-trisphosphate (PIP3) at the 
postsynaptic terminal is necessary for sustaining synaptic function. This requirement is 
specific for synaptic, but not for extrasynaptic, AMPA receptors, nor NMDA receptors. 
We found that PIP3 down-regulation impairs PSD-95 accumulation in spines. 
Concomitantly, AMPA receptors become more mobile and migrate from the 
postsynaptic density towards the perisynaptic membrane within the spine, leading to 
synaptic depression. Interestingly, these effects are only revealed after prolonged 
inhibition of PIP3 synthesis or by direct quenching of this phosphoinositide at the 
postsynaptic cell. Therefore, we conclude that a slow, but constant turnover of PIP3 at 
synapses is required for maintaining AMPA receptor clustering and synaptic strength 
under basal conditions. 
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Phosphoinositides (phosphorylated derivatives of phosphatidylinositol) are 
fundamental second messengers in the cell. They are able to integrate multiple 
intracellular signaling pathways and modulate a large spectrum of cellular activities1. 
Phosphoinositides are highly compartmentalized in different intracellular organelles and 
the plasma membrane, and in this fashion, they are thought to provide essential spatial 
and temporal cues for protein recruitment and intracellular membrane trafficking2. The 
functional role of phosphoinositide metabolism and compartmentalization has been 
studied with great detail at the presynaptic terminal, where phosphoinositide turnover 
has been shown to be critical for neurotransmitter vesicle cycling and synaptic function3. 
There is also abundant evidence for the relevance of phosphoinositide pathways for 
synaptic plasticity4-8. However, very little is known about specific roles of 
phosphoinositides in membrane trafficking at the postsynaptic terminal, despite the 
importance of neurotransmitter receptor trafficking for synaptic plasticity9,10. 
Phosphatidylinositol-(3,4,5)-trisphosphate (PIP3) is among the most elusive 
phosphoinositides. Basal levels of PIP3 are extremely low, due to a tight spatial and 
temporal regulation of PIP3 synthesis11. Nevertheless, PIP3 can be found enriched in 
specific subcellular compartments, such as the tip of growing neurites12. The regulated 
synthesis of PIP3 by phosphatidylinositol-3-kinases (PI3Ks) is thought to be important 
for polarized exocytosis. For example, in adipocytes, PI3K activation has been shown to 
be both necessary and sufficient for the insulin-triggered insertion of the glucose 
transporter Glut4 from intracellular stores into the plasma membrane13. PI3K is also 
responsible for the regulated delivery of voltage-gated calcium channels to the plasma 
membrane in myocytes and neurons14. In addition, local accumulation of PIP3 is very 
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important for the establishment of cell polarity, including neuronal differentiation and 
dendritic arborization15,16. The mechanisms by which PIP3 exerts these diverse 
functions are still being elucidated. Nevertheless, a common theme is the role of PIP3 
as a landmark for docking and co-localization of a variety of signaling molecules at the 
plasma membrane1. 
AMPA-type glutamate receptors (AMPARs) mediate most excitatory transmission 
in the brain, and their regulated addition and removal from synapses leads to long-
lasting forms of synaptic plasticity such as long-term potentiation (LTP) and long-term 
depression (LTD)17. In addition to the activity-dependent trafficking during plasticity, 
AMPARs continuously cycle in and out of the synaptic membrane, in a manner that 
does not require synaptic activity. This constitutive trafficking involves both exocytic 
delivery from intracellular compartments18 and fast exchange with surface extrasynaptic 
receptors via lateral diffusion19. According to this dynamic behavior, multiple proteins 
have been described to interact with AMPARs and affect their synaptic localization20. 
Still, we know very little about the organization and regulation of AMPARs within the 
synaptic terminal. In particular, the potential role of PIP3 in these processes has never 
been explored. 
In this work we have investigated specific actions of PIP3 at the postsynaptic 
membrane, using a combination of pharmacological and molecular tools, together with 
electrophysiology, fluorescence imaging and electron microscopy assays. Surprisingly, 
we have found that PIP3 is continuously required for the maintenance of AMPARs at the 
synaptic membrane. This effect is only visible upon direct PIP3 quenching or prolonged 
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inhibition of its synthesis, suggesting that a slow but constant turnover of PIP3 is 
required for sustaining synaptic function. 
 
RESULTS 
PIP3 is a limiting factor for AMPA receptor-mediated synaptic transmission 
As a first step to evaluate the role of PIP3 in synaptic transmission, we 
manipulated endogenous PIP3 levels using two independent approaches: i) quenching 
PIP3 availability in the postsynaptic cell by sequestering it with a specific PIP3-binding 
domain, and ii), blocking PIP3 synthesis by pharmacological inhibition of class I 
phosphatidylinositol-3-kinases (PI3Ks), the enzymes that generate PIP3. For the first 
approach, we overexpressed the pleckstrin homology (PH) domain from General 
Receptor for Phosphoinositides (GRP1) in CA1 neurons from organotypic hippocampal 
slice cultures (see Methods). This domain has a 650-fold specificity for PIP3 versus PIP2 
and other phosphoinositides21, and it has a dominant negative effect on PIP3-dependent 
processes by restricting binding to the endogenous targets22. As shown in Fig. 1A, this 
construct (PH-GRP1) is well expressed in neurons, where it reaches dendritic spines. 
The lack of an obvious membrane distribution of this recombinant protein is consistent 
with the presence of very low levels of PIP3 under basal conditions11. That is, PH-GRP1 
is expected to be well in excess over endogenous PIP321, as it would be required for 
PH-GRP1 to act as a dominant negative. Nevertheless, we have confirmed the PIP3-
binding ability and specificity of PH-GRP1 in vitro (Fig. 1B, C) and in BHK cells upon 
PIP3 up-regulation (Fig. 1D). 
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We then monitored the effect of PIP3 quenching with PH-GRP1 on evoked 
AMPAR- and NMDAR-mediated responses in CA1 pyramidal neurons using whole-cell 
simultaneous double recordings. Importantly, only CA1 (but not CA3 cells) express the 
recombinant protein. Therefore, PIP3 levels are only altered in the postsynaptic cell 
when monitoring CA3-to-CA1 synaptic transmission. As shown in Fig. 2A, quenching of 
PIP3 with PH-GRP1 caused a significant and selective depression of AMPAR synaptic 
responses compared to control neighboring pyramidal neurons. Recordings at +40mV 
revealed no effect on NMDAR transmission (for simplicity, only average values are 
plotted in the graphs, but statistical comparisons are always calculated for infected-
uninfected paired data). Importantly, expression of PH-GRP1 did not affect passive 
membrane properties of the cell, such as holding current or input resistance, indicating 
that cell-wide ion channel conductances were not altered. In addition, cell size, as 
reported by whole-cell capacitance was not affected either (Supplementary Fig. 1). 
Therefore, overnight expression of this construct does not appear to have any general 
toxic effect in neurons from organotypic slices. 
 PH domains have been reported to have cellular effects independent from their 
phosphoinositide binding activity23. Therefore, we tested whether the depression of 
AMPAR transmission by PH-GRP1 was directly due to PIP3 sequestration. To this end, 
we expressed a PH-GRP1 domain with a point mutation that specifically prevents 
phosphoinositide binding: R284C23. As shown in Fig. 2B, paired recordings for AMPAR- 
and NMDAR-mediated transmission revealed no difference in synaptic responses 
between cells expressing PH-GRP1-R284C and their control neighbors. These results 
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confirm that the binding and thus sequestering of PIP3 causes the depression of 
AMPAR-mediated transmission. 
 As an independent approach to test the role of PIP3 in synaptic transmission, we 
used specific inhibitors of PI3K to depress basal PIP3 levels in neurons. For these 
experiments we pre-treated hippocampal slices with 10 µM LY294002 or 100 nM 
wortmannin for one hour prior to whole-cell recordings (these drugs were also present in 
the perfusion solution during the recordings). Importantly, at these concentrations, 
LY294002 and wortmannin are potent inhibitors of PI3K, without significant effects on 
phosphoinositide kinases required for PI(4,5)P2 synthesis11. Synaptic responses were 
evoked at -60 mV and +40 mV holding potentials to obtain AMPA/NMDA ratios (Fig. 
2C). Compared to the equivalent vehicle control (0.05% DMSO, by volume), 
AMPA/NMDA ratio was significantly decreased in cells treated with LY294002 or 
wortmannin. Finally, depression of AMPA/NMDA ratios was observed in both cultured 
and acute hippocampal slices (Fig. 2C, right histogram). 
 To test whether pharmacological inhibition of PI3K and overexpression of PH-
GRP1 depress synaptic transmission by the same mechanism, we carried out an 
occlusion experiment. We compared AMPAR and NMDAR responses between PH-
GRP1-expressing and control neurons, after pre-treating the slices with 10 µM 
LY294002 for 1 hour (LY294002 was also present during the recordings). As shown in 
Fig. 2D, PH-GRP1 expression did not alter AMPAR nor NMDAR currents with respect to 
the control neuron when PIP3 synthesis was inhibited. This result confirms that these 
molecular (PH-GRP1) and pharmacological (LY294002) manipulations depress synaptic 
transmission through the same pathway, most likely by limiting PIP3 availability. 
 8
This observed depression of AMPAR-mediated transmission upon PIP3 depletion 
suggests that PIP3 may be a limiting factor for AMPAR synaptic function. If this is the 
case, enhanced PIP3 synthesis might lead to increased AMPAR responses. To test this 
possibility, we generated a constitutively active PI3K by permanently targeting its 
catalytic subunit (p110) to the plasma membrane using a myristoylation tag (Myr-p110, 
24). The efficacy of this construct to upregulate PIP3 signaling was confirmed by 
monitoring Akt phosphorylation in CA1 neurons expressing Myr-p110 (Supplementary 
Fig. 2). To evaluate the effect of PIP3 upregulation on synaptic transmission, we carried 
out simultaneous dual whole-cells recordings, as described above, and compared 
evoked AMPAR and NMDAR responses between infected and non-infected neighboring 
pyramidal neurons at -60 mV and +40 mV. Neurons expressing Myr-p110 displayed a 
significant potentiation of AMPAR transmission (Fig. 2E) with no alteration of NMDAR 
responses. Passive membrane properties including holding current, input resistance 
and capacitance were not different between infected and uninfected cells 
(Supplementary Fig. 1). These results support the interpretation that PIP3 is a limiting 
factor controlling AMPAR synaptic function. 
 
Gradual depression of synaptic transmission upon inhibition of PIP3 synthesis 
 Our combined results using pharmacological inhibition of PIP3 synthesis and 
direct quenching of postsynaptic PIP3 strongly suggest that this phosphoinositide is 
required for maintaining AMPAR-mediated synaptic responses. However, previous 
reports using PI3K inhibitors have yielded conflicting results on the role of PIP3 on basal 
synaptic transmission4,5. In this context, it is important to keep in mind that the 
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magnitude of the decrease in PIP3 levels upon blockade of its synthesis will depend on 
its metabolic turnover under basal conditions. Thus, short incubations with PI3K 
inhibitors may be ineffective if basal PIP3 turnover is slow. To directly address this 
possibility, we incubated hippocampal slices with 10 μM LY294002 for up to two hours 
while monitoring AMPAR synaptic responses using field recordings. 
 Stable baselines of a minimum of 25 minutes were obtained from hippocampal 
slices prior to infusion of 10 μM LY294002 or 0.05% DMSO (vehicle control). As shown 
in Fig. 3A, B, slices treated with 10 μM LY294002 displayed a slow and gradual run-
down of synaptic transmission, which started to be significant 60-80 min after the onset 
of PI3K inhibition. In contrast, DMSO-treated slices showed a small decrease in 
synaptic responses, which was not significant after 2 hours of infusion. As control, 
treatment with LY294002 did not affect fiber volley amplitude (Fig. 3A, C), suggesting 
that presynaptic excitability was not altered over the time course of these experiments. 
Therefore, these results confirm our previous conclusion on the importance of PIP3 for 
the maintenance of AMPAR synaptic function. In addition, these data support the 
interpretation that PIP3 undergoes a slow turnover under basal conditions, which is only 
revealed after prolonged inhibition of PIP3 synthesis (to note, recordings in Fig. 2C 
started one hour after application of LY294002). 
 
Depletion of PIP3 does not alter extrasynaptic AMPA receptor function 
 Both pharmacological PI3K inhibition and direct PIP3 quenching indicate that 
PIP3 is required for synaptic responses mediated by AMPARs (Figs. 2 and 3). The 
function of some ion channels has been shown to be directly modulated by 
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phosphoinositides, more typically by PIP2 (see for example 25), but also by PIP326. In 
order to test whether this is the case for AMPARs, we recorded extrasynaptic responses 
evoked by bath application of AMPA (100 nM) from CA1 neurons expressing PH-GRP1 
and from neighboring control cells. Recordings were carried out in the presence of 0.5 
µM tetrodotoxin (to prevent action potential firing) and 10 μM cyclothiazide (to prevent 
AMPAR desensitization). As shown in Fig. 3D, whole-cell AMPA-evoked currents were 
similar in PH-GRP1-expressing neurons and in control neighboring cells. This result 
suggests that the requirement for PIP3 is specific for synaptic AMPARs. 
 
Postsynaptic PIP3 is necessary for long-term potentiation 
 There have been previous conflicting results on the role of PIP3 in LTP induction, 
maintenance or both4,5. However, it is important to note that pharmacological inhibition 
of PI3K would affect both pre- and postsynaptic cells. In addition, as discussed above, 
different incubation times with PI3K inhibitors may yield variable depletion of basal PIP3 
levels. In order to circumvent these complications, we decided to test the role of PIP3 in 
LTP by directly quenching this phosphoinositide in the postsynaptic cell using PH-GRP1 
in organotypic hippocampal slices. Importantly, this experimental manipulation does not 
affect NMDAR synaptic currents (Fig. 2A), and therefore, it rules out potential effects on 
LTP induction. 
 Whole-cell recordings were obtained from neurons expressing PH-GRP1 and 
from control, uninfected neurons, in an interleaved manner. LTP was induced according 
to a pairing protocol (see Methods). As shown in Fig. 4A, B, control cells displayed 
significant potentiation of transmission compared to the unpaired pathway that did not 
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receive LTP-inducing stimulation. In contrast, LTP expression was abolished in cells 
expressing PH-GRP1 (black symbols in panel A; black column in panel B). 
 
PIP3 is necessary for the constitutively cycling and regulated populations of 
AMPA receptors 
 Most AMPARs in the hippocampus are composed of GluA1/GluA2 or 
GluA3/GluA2 subunit combinations27 (also known as GluR1/GluR2, GluR3/GluR2; 
subunit nomenclature according to 28). These two populations appear to reach their 
synaptic targets according to different pathways, with GluA2/3 continuously cycling in 
and out of synapses and GluA1-containing receptors undergoing acute, activity-
dependent synaptic delivery29 (but see also 30). Therefore, we decided to separately test 
the PIP3 requirements of these two populations. 
To this end, we co-expressed individual EGFP-tagged AMPAR subunits with 
either RFP or an RFP-tagged PH-GRP1 in organotypic slice cultures using the biolistic 
delivery system (see Methods). When overexpressed, these subunits form homomeric 
receptors, which can be detected at synapses from their inward rectification 
properties31,32 (in the case of GluA2, we used the unedited version R607Q). Inward 
rectification can then be quantified as the ratio of the synaptic response at -60 mV 
versus +40 mV (rectification index). Recombinant GluA2 receptors behave as 
endogenous GluA2/3 heteroligomers31; thus, they can be used to monitor the 
constitutively cycling population of AMPARs. When GluA2(R607Q) was expressed with 
RFP, the rectification index was significantly increased compared to non-transfected 
cells (Fig. 4C; compare first and second columns), indicating presence of the 
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recombinant receptor at the synapse. In contrast, when GluA2(R607Q) was 
coexpressed with PH-GRP1, this increase in rectification was abolished (Fig. 4C; 
compare second and third columns), indicating that PIP3 is needed for the delivery 
and/or stability of this population of AMPARs at synapses. 
Similar assays were carried out with recombinant GluA1 subunits to monitor the 
activity-regulated population of AMPARs32. GluA1 is driven into synapses when co-
expressed with a constitutively-active form of αCaMKII (tCaMKII), as judged from the 
increase in the rectification index (Fig. 4C, compare first and fourth columns). However, 
when PH-GRP1 is co-expressed with GluA1 and tCaMKII, this increase in rectification is 
not observed (Fig. 4C; compare fourth and fifth columns). This finding suggests that 
PIP3 is also necessary for the synaptic presence of this population of AMPARs. 
 These results were essentially replicated using the PI3K inhibitor LY294002 (10 
µM) on hippocampal slices expressing either GluA2(R607Q) or GluA1 plus tCaMKII. For 
these experiments, recombinant receptors were expressed for 36 hours, and slices 
were then treated with 10 µM LY294002 (or DMSO vehicle) for one hour prior to 
recordings (LY294002 or DMSO were also present during the recordings). As shown in 
Fig. 4D, PI3K inhibition also prevented the appearance of recombinant GluA1 and 
GluA2 receptors at synapses, as evidenced from the blockade of the increase of the 
rectification index. 
These experiments using recombinant receptors fit very well with our results 
monitoring endogenous AMPARs during basal synaptic transmission and LTP. When 
taken together, these data strongly suggest that PIP3 is a common requirement for all 
populations of AMPARs. 
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Depletion of PIP3 causes local accumulation of AMPA receptors at spines 
The results described above suggest that PIP3 availability affects synaptic, but 
not extrasynaptic AMPARs. Therefore, we hypothesized that PIP3 may play a local role 
in AMPAR function at synapses. To address this hypothesis, we evaluated the 
distribution of AMPARs at dendritic spines upon PIP3 depletion. 
We used biolistic gene delivery to co-express EGFP-tagged GluA2 together with 
either RFP (control) or an RFP-tagged PH-GRP1, in organotypic hippocampal slices. 
The partition of GluA2 between spines and dendrites was estimated from the intensity of 
the GFP signal in the spine head versus the adjacent dendritic shaft (see Methods). 
Similarly, the surface distribution of the recombinant receptor in spines and dendrites 
was assessed by immunostaining with an anti-GFP coupled to an infrared fluorophore 
(Cy5) under non-permeabilized conditions (the GFP tag is placed at the extracellular N 
terminus of the receptor; see Supplementary Fig. 3 for a control of the non-
permeabilizing conditions for surface immunostaining). This experimental design allows 
us to monitor the amount of total receptor (GFP channel), the fraction of receptor 
exposed to the surface (Cy5 channel) and the presence of the coexpressed PH-GRP1 
(RFP channel) (see Fig. 5A for examples). 
As shown in Fig. 5B, GluA2 partitions almost equally between the spine head 
and the adjacent dendrite when expressed with RFP (spine/dendrite ratio = 1.15 ± 0.2) 
To our surprise, co-expression with PH-GRP1 led to a small, but significant increase in 
the amount of GluA2 receptor in the spine (Fig. 5B, left pair of columns). Notably, PH-
GRP1 produced a similar accumulation of GluA2 at the plasma membrane (surface) of 
the spine (Fig. 5B, right pair of columns). This redistribution appears to be local, since 
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long-range distribution of GluA2 along the primary apical dendrite was not altered by 
PH-GRP1 expression (Supplementary Fig. 4). 
Similar to our electrophysiological data, these results were replicated using a 
pharmacological approach to inhibit PIP3 synthesis. That is, total and surface GluA2-
GFP accumulated at the spine head upon incubation with 10 μM LY294002 (Fig. 5C). 
Importantly, spine size (estimated from cytosolic GFP distribution) and distribution of the 
PIP3 precursor, phosphatidylinositol-(4,5)-bisphosphate (PIP2) at spines were not 
altered upon PIP3 blockade (Supplementary Fig. 5). Therefore, these combined data 
indicate that PIP3 depletion leads to a local redistribution of AMPARs, which 
unexpectedly, accumulate in spines. As will be shown below, ultrastructural analyses 
indicated that this receptor accumulation occured on the extrasynaptic region of the 
spine plasma membrane (Fig. 7). 
 
PIP3 contributes to PSD-95 accumulation in spines 
 PSD-95 is a synaptic scaffolding molecule that critically controls the 
accumulation of AMPARs at synapses, and accordingly, it is a determining factor for the 
maintenance of synaptic strength33. PSD-95 has not been shown to bind PIP3 directly; 
however, several PDZ domains display weak phosphoinositide binding34, and there is a 
high degree of crosslinking interactions among synaptic scaffolding proteins20. 
Therefore, we decided to test whether PIP3 may affect PSD-95 accumulation at 
synapses. To this end, we co-expressed GFP-tagged PSD-95 with plain (cytosolic) RFP 
or with RFP-PH-GRP1 in CA1 neurons from organotypic slice cultures (see Fig. 6A for 
representative examples). The accumulation of PSD-95 in spines was then quantified 
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from the ratio of GFP fluorescence at the spine head versus the adjacent dendritic shaft. 
As shown in Fig. 6B, co-expression with PH-GRP1 significantly reduced the 
accumulation of PSD-95 in spines, as compared with RFP-expressing neurons. This 
reduction was detected across the whole population of spines (see cumulative 
distribution in Fig. 6C). Importantly, as mentioned earlier, PIP3 depletion did not alter 
spine size (Supplementary Fig. 5A). Therefore, these results strongly suggest that PIP3 
availability is important for PSD-95 enrichment in spines. 
 
PIP3 depletion increases AMPA receptor mobility at the surface of dendritic 
spines 
 PSD-95 is a critical factor for the stability of AMPARs at the synaptic 
membrane35. Therefore, the results shown above suggest that the depression of 
synaptic strength upon PIP3 depletion may be due to a reduction in PSD-95-mediated 
anchoring of AMPARs at synapses. As an initial approach to test this hypothesis, we 
evaluated the mobility of AMPARs at the surface of dendritic spines using fluorescence 
recovery after photobleaching (FRAP) and Super-Ecliptic-pHluorin-tagged GluA2 (SEP-
GluA2). Super-ecliptic-pHluorin is a highly pH-sensitive version of GFP, which has been 
previously used to track surface AMPARs36. 
 SEP-GluA2 receptors were expressed in organotypic hippocampal slices, and 
PIP3 levels were reduced by treatment with the PI3K inhibitor LY294002, in the same 
manner as previous experiments. Spines expressing SEP-GluA2 were photobleached 
and the extent of fluorescence recovery was measured over 30 minutes (see examples 
of representative experiments in Fig. 6D). As shown in Fig. 6E, approximately 25% of 
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the SEP-GluA2 signal is recovered in the spine over a time course of 5-10 min (time 
constant of 5.7 min). In contrast, in slices treated with LY294002, SEP-GluA2 
fluorescence recovered to a significantly greater extent (around 50%) over a similar time 
course (time constant of 5.9 min). These results indicate that PIP3 depletion leads to an 
increase in the fraction of AMPARs that are free to exchange between the dendrite and 
the spine. As a control, the mobility of a membrane-anchored version of GFP (GFP with 
the farnesylation sequence of H-Ras) was not altered by LY294002 (Supplementary 
Fig. 6). In addition, similar FRAP experiments monitoring GFP-GluA2 in dendrites 
indicate that PIP3 depletion does not change the mobility of dendritic AMPARs 
(Supplementary Fig. 7). Therefore, these combined observations indicate that PIP3 
specifically modulates the flow of AMPARs between the spine and the dendrite, in a 
manner that is consistent with a decreased stability of receptors at the synaptic 
membrane in the absence of PIP3. 
PSD-95 anchors AMPARs at synapses through its interaction with 
transmembrane AMPAR regulatory proteins (TARPs)33,35. We then tested whether PIP3 
is required for PSD-95/TARP interaction. To this end, we inhibited PIP3 synthesis in 
hippocampal slices with LY294002 for 2 hours, prepared total protein extracts, and 
carried out co-immunoprecipitations between PSD-95 and two major TARPs expressed 
in the hippocampus: γ-8 and γ-2 (stargazin)37. As shown in Supplementary Fig. 8, PSD-
95 can be immunoprecipitated with both γ-8 and γ-2 from hippocampal extracts. 
Surprisingly, this interaction appeared to be stronger in slices pre-treated with 
LY294002. The mechanism for this unexpected strengthening of PSD-95/TARP 
interaction upon PIP3 depletion is unclear. Nevertheless, we can conclude that the 
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depression of synaptic responses and increased mobility of surface AMPARs induced 
by PIP3 depletion are not due to an impaired interaction between PSD-95 and TARPs. 
 
PIP3 is necessary for the clustering of AMPA receptors at the postsynaptic 
membrane of the spine 
One of the most surprising results of this work is that AMPARs accumulate at the 
spine plasma membrane upon PIP3 depletion (Fig. 5), although synaptic transmission is 
depressed (Figs. 2 and 3). However, it should be kept in mind that only a small fraction 
(around 15%) of the spine plasma membrane is actually occupied by the postsynaptic 
density, where excitatory transmission occurs38. At this submicron scale, confocal 
fluorescence microscopy cannot easily resolve whether receptors present on the spine 
surface are actually located on the synaptic membrane. To directly evaluate whether 
PIP3 affects AMPAR clustering at the postsynaptic membrane, we employed post-
embedding immunogold electron microscopy. In addition to its high spatial resolution, 
this technique has the advantage of monitoring endogenous AMPARs. 
 Hippocampal slices were treated with 10 µM LY294002 (or DMSO, as control), 
and processed for postembedding immunogold detection using anti-GluA2 antibodies 
(see Methods). Electron micrographs were sampled randomly from excitatory 
(asymmetric) synapses in the stratum radiatum (CA1) (see representative images in 
Fig. 7A). The abundance of anti-GluA2 immunogold particles was quantified at three 
compartments: the postsynaptic density, the extrasynaptic membrane lateral to the PSD 
and the intracellular space within the spine. Interestingly, slices treated with LY294002 
displayed a significant accumulation of GluA2 particles in the extrasynaptic membrane 
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lateral to the PSD (Fig. 7B). This effect was accompanied by a decrease in the PSD 
population, resulting in no net change in total membrane localization (PSD plus 
extrasynaptic membrane) versus intracellular fraction (Fig. 7B). 
Prompted by this result, we took a closer inspection to the distribution of GluA2 
along the synaptic and perisynaptic membrane within the spine. To this end, we 
measured the lateral distance of each individual gold particle in these two 
compartments with respect to the closest PSD edge. Particles within the extrasynaptic 
membrane are given positive distances (larger numbers representing particles farther 
away from the PSD edge) and particles within the PSD are given negative distances 
(larger numbers representing particles closer to the center of the PSD). Only particles 
within 290 nm (average PSD length) were considered for this analysis. As shown in Fig. 
7C, D, under control conditions, AMPARs accumulate to higher densities within the PSD 
membrane, whereas the perisynaptic membrane near the PSD edge remains rather 
unpopulated by receptors. In contrast, upon PIP3 depletion, the distribution of AMPARs 
becomes much more homogeneous along synaptic and extrasynaptic membrane within 
the spine: AMPAR immunolabeling decreases at the PSD and increases in the 
perisynaptic membrane (Fig. 7C), to the point that receptor density does not appreciably 
change across the PSD edge (see cumulative distributions in Fig. 7D). Similar results 
were obtained with a different antibody monitoring the GluA3 subunit of AMPARs 
(Supplementary Fig. 9). Therefore, this analysis confirms that PIP3 depletion leads to a 
very local, but critical, redistribution of AMPARs within the spine surface, which results 
in a decreased receptor density at the synaptic membrane and an increased receptor 
accumulation on the extrasynaptic surface of the spine. 
 19
 Importantly, this result monitoring endogenous receptors is consistent with the 
depression of AMPAR synaptic responses produced by PH-GRP1 expression or 
LY294002 treatment (Figs. 2 and 3), and it also fits with the increased fraction of mobile 
recombinant receptors reported by FRAP measurements (Fig. 6) (receptors on the 
perisynaptic membrane exchange more readily with extrasynaptic receptors than those 
at the postsynaptic site19). Taken together, these results indicate that PIP3 has a critical 
role in the subsynaptic distribution and dynamics of AMPARs, which bears direct 
consequences for the maintenance of synaptic function. 
 
Perisynaptic AMPA receptors induced by PIP3 depletion are detectable 
electrophysiologically after blocking glutamate uptake 
 In order to functionally evaluate the presence of perisynaptic receptors induced 
by PIP3 depletion, we decided to test the effect of PH-GRP1 on synaptic responses 
elicited in the presence of a glutamate reuptake blocker. The rationale is that 
synaptically released glutamate may reach these nearby receptors if neurotransmitter 
reuptake is inhibited. To this end, we pre-incubated slices with the glutamate uptake 
blocker L-trans-pyrrolidine-2,4-dicarboxylate (L-t-PDC). This is a potent uptake inhibitor 
that does not have any direct action on glutamate receptors39. As shown in Fig. 8A, 
AMPAR-mediated synaptic responses from neurons expressing PH-GRP1 are no 
longer depressed with respect to control neurons in the presence of L-t-PDC (compare 
with Fig. 2A). This result supports our interpretation that PIP3 depletion leads to AMPAR 
diffusion into the perisynaptic membrane of the spine. These receptors would be able to 
contribute to synaptic responses when glutamate uptake is blocked pharmacologically. 
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 Nevertheless, it is worth pointing out that the effects of blocking neurotransmitter 
reuptake are not necessarily straightforward. It has been previously reported that 
inhibition of glutamate uptake produces depression of basal synaptic transmission in 
primary neuronal cultures40 and in hippocampal slices41 (but see also 42). This 
depression is thought to be mediated by the activation of metabotropic glutamate 
receptors40. Indeed, we observed a run-down of basal synaptic transmission in control 
neurons when perfusing L-t-PDC (Fig. 8B; white symbols). In the case of PIP3-depleted 
neurons (PH-GRP1), this depression was greatly reduced or completely absent (Fig. 
8B, black symbols). This result is consistent with the additional contribution of nearby 
extrasynaptic receptors in these neurons, which would compensate from the depression 
otherwise induced by blocking glutamate uptake. Since PH-GRP1 neurons start from an 
already depressed situation (Fig. 2A), by the end of the incubation with L-t-PDC they 
display similar AMPAR responses as to those from control neurons (see Fig. 8B, inset, 
for a representative pair of infected and uninfected neurons recorded simultaneously). 
Regardless of the macroscopic effects of L-t-PDC on basal synaptic 
transmission, the fact that blockade of glutamate uptake abolishes the depression 
induced by PIP3 depletion strongly supports the interpretation that AMPARs redistribute 
to the nearby perisynaptic membrane in the absence of PIP3. 
 
DISCUSSION 
 In this manuscript we have shown that PIP3 is a critical effector of AMPAR 
synaptic function and plasticity, and that it is required for the maintenance of synaptic 
strength. This is based on a combination of electrophysiological and imaging 
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techniques, using both pharmacological and genetic approaches to modulate 
endogenous PIP3 levels in hippocampal neurons. In particular, we have found that PIP3 
down-regulation leads to a depression of synaptic transmission, which is specific for 
synaptic AMPARs, since it does not affect NMDAR nor extrasynaptic AMPAR currents. 
Interestingly, PIP3 seems to act at a very local scale, by ensuring PSD-95-mediated 
clustering of AMPARs at the postsynaptic membrane, and therefore, preventing 
receptor dispersion into the neighboring extrasynaptic membrane of the spine. In 
addition, PIP3 depletion leads to the accumulation of AMPARs in spines, possibly 
through a separate mechanism that remains to be characterized. 
 These results clarify previous conflicting reports on the role of PIP3 signaling for 
synaptic function and plasticity. We report for the first time that basal levels of PIP3 at 
the postsynaptic terminal are necessary for sustaining synaptic function. Importantly, 
this requirement is only unmasked when blocking PI3K activity for long periods of time 
(> 1 hour), suggesting that PIP3 levels (at least at synapses) are subject to a slow 
turnover. This is an important finding for synaptic signaling, since it implies that both 
synthetic (PI3K) and degradative (PTEN and/or SHIP) activities are present in 
unstimulated neurons. Our results suggest that, under basal conditions, these activities 
are tuned to maintain low (but physiologically relevant) levels of PIP3. Obviously, this 
interpretation also includes the possibility of fast regulation of PIP3 levels during 
plasticity. In fact, LTP induction and NMDAR activation have been previously reported 
to trigger the PI3K signaling cascade 43,44. According to this scenario, acute blockade of 
PI3K during LTP induction should be sufficient to prevent the fast up-regulation of PIP3 
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and synaptic potentiation. However, prolonged blockade of PIP3 synthesis would be 
needed to unveil its requirement for the maintenance of synaptic transmission. 
 This interpretation begs the question of how PI3K activity is maintained (even if 
at low levels) under basal conditions. This is an important point, since PI3K is usually 
seen as a regulated enzyme that is activated by upstream effectors (receptor protein 
tyrosine kinases, G protein coupled receptors, etc.; see 1 for a review). However, it is 
worth noting that most PI3K activating mechanisms operate by recruiting the enzyme to 
the plasma membrane, where its substrate, PIP2, is found. In fact, “passive” targeting of 
PI3K to the plasma membrane (in the absence of receptor stimulation) leads to a 
constitutive up-regulation of PIP3 signaling24 (see also Supplementary Fig. 2). 
Interestingly, it has been shown that PI3K is localized at excitatory synapses, and that it 
directly binds the cytosolic C-terminus of the AMPAR6. This interaction is constitutive 
and preserves the catalytic activity of PI3K6. Therefore, we propose that, via its 
association to AMPARs, PI3K would be maintained in close proximity to the synaptic 
membrane, where it would responsible for supplying a low but constant level of PIP3 
necessary to sustain synaptic transmission. 
 Why is PIP3 constantly needed at the postsynaptic membrane? To some extent, 
this situation is reminiscent of the presence of PIP3 in subcellular domains with high 
membrane dynamics, such as the tip of growing neurites12. Although the precise role of 
PIP3 in this process is far from clear, a recurring theme is the requirement of PIP3 for the 
establishment or maintenance of cell membrane polarity12,15,16. We now know that the 
postsynaptic terminal is indeed a domain of intense and polarized membrane dynamics, 
which is critical for both synaptic function maintenance and plasticity10. Therefore, our 
 23
results suggest that a slow, but active, turnover of PIP3 may be critical for subserving 
basal membrane dynamics constantly operating at the postsynaptic terminal. 
 Finally, our data indicate that PIP3 plays a very distinct and local function for the 
regulation of AMPARs at synapses. Specifically, we have found that PIP3 contributes to 
the accumulation of PSD-95 at spines. Accordingly, PIP3 depletion produces an 
enhanced mobility of AMPARs in spines, which is accompanied by receptor dispersion 
into the perisynaptic membrane. Therefore, our results suggest that PIP3 is a critical 
factor for the synaptic retention of AMPARs, perhaps via modulation of the PSD-95 
synaptic scaffold. This mechanism is likely to be specific for AMPARs, since knock-
down of PSD-95 does not significantly alter synaptic NMDARs45. The mechanistic link 
between PIP3 and PSD-95 remains to be elucidated. It has been recently shown that a 
variety of PDZ domains and polybasic clusters confer phosphoinosotide binding 
specificity34,46,47. Therefore, the recruitment of PSD-95 into spines may be modulated by 
a complex network of phosphoinositide-dependent interactions. 
 In summary, this work has offered new insights into the complex interplay 
between lipids and neurotransmitter receptors for the regulation of synaptic function. In 
addition, it has revealed that an important but poorly understood phosphoinositide, 
phosphatidylinositol-(3,4,5)-trisphosphate, is a critical factor for the local concentration 
of AMPARs at the postsynaptic membrane. 
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FIGURE LEGENDS 
 
Figure 1. Expression of PH-GRP1 in hippocampal neurons and specific binding to 
PIP3. A. Expression of PH-GRP1-GFP in the soma, dendrites, and dendritic spines 
(inset) of CA1 pyramidal neurons in organotypic cultures. B. Protein extracts from 
hippocampal slices expressing GFP (lanes 1, 4-6), GFP-PH-PLC (lanes 2, 7-9), or GFP-
PH-GRP1 (lanes 3, 10-12) were incubated with agarose beads (Echelon) covalently 
linked to PIP2 (lanes 5, 8, 11), PIP3 (lanes 6, 9, 12), or control beads (lanes 4, 7, 10). 
Pull down fractions were analyzed by western blot with anti-GFP antibody (Roche). 
Input extracts: lanes 1-3. C. Similar extracts to those used in (B) were incubated with 
membranes spotted with an array of different phospholipids and phosphoinositides (see 
http://echelon-inc.com for a full list of lipid abbreviations). Membrane bound fractions 
were visualized with anti-GFP (Roche). D. Representative example of BHK cells 
expressing GFP-PH-GRP1 before (left) and after (right) stimulation with peroxyvanadate 
(5 min incubation with 30 µM peroxide, 100 µM ortho-vanadate). Line plots show 
quantification of fluorescence intensity across the cell. Note accumulation of GFP-PH-
GRP1 at the cell edge (plasma membrane) after stimulation. 
 
Figure 2. Bidirectional modulation of AMPA-receptor mediated currents by PIP3. 
A, B, D, E. Comparison of evoked synaptic responses from pairs of neighboring CA1 
neurons expressing PH-GRP1 (A, D), PH-GRP1-R284C (B) or Myr-p110 (E), and 
control (uninfected) neurons recorded at -60 mV (AMPAR EPSCs) and +40 mV 
(NMDAR EPSCs). Some slices were pre-treated for 1 hour with 10 μM LY-294002 (D). 
Example traces from uninfected and infected neurons are shown on the left for all 
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panels. “n” represents number of cell pairs. Statistical significance was calculated 
according to the Wilcoxon text for paired data (individual pairs of infected versus 
uninfected cells). C. Comparison of evoked synaptic responses from CA1 neurons pre-
treated for 1 hour with 10 µM LY-294002 (“LY”) or 100 nM wortmannin (“Wrt”) or with 
the vehicle control (0.05% DMSO). The AMPA/NMDA ratio is calculated from the size of 
the AMPAR- and NMDAR-mediated responses recorded at -60 mV and +40 mV, 
respectively. Experiments were carried out on organotypic cultured slices (left 
histrogram) or on acute slices (14 days postnatal; right histogram). Representative 
traces are shown on the left. “n” represents number of cells; “p” values were calculated 
according to the Mann-Whitney test. 
 
Figure 3. Inhibition of PIP3 synthesis produces a slow and gradual depression of 
AMPA receptor-mediated transmission. A. Examples of evoked field excitatory 
postsynaptic potentials (fEPSP) obtained from hippocampal slices 5-25 minutes before 
(“baseline”) or 120-140 minutes after (“120-140”) treatment with DMSO (left) or 10 μM 
LY294002 (right). Presynaptic fiber volleys and fEPSPs are indicated with arrows. B. 
Time course of the slope of fEPSP responses from hippocampal slices treated with 10 
µM LY294002 (black symbols) or DMSO (white symbols) (drug application is shown 
with a black bar). Values are normalized to the average slope before drug application. 
“n” represents number of slices. Statistical significance for the comparison between 
DMSO- and LY294002-treated slices was done according to the Mann-Whitney test. C. 
The amplitude of the presynaptic fiber volley was analyzed from the experiments shown 
in B. Values are normalized to the average fiber volley amplitude before drug 
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application. No significant change in fiber volley amplitude was observed over the time 
course. D. Time course of whole-cell currents recorded from CA1 pyramidal neurons 
infected with PH-GRP1 (black symbols) or uninfected control neurons (white symbols) 
during the application of 100 nM AMPA (bar). “n” represents number of cells. 
 
Figure 4. PIP3 is required for LTP and it affects both constitutively cycling and 
regulated populations of AMPA receptors. A. Time course of AMPAR-mediated 
synaptic responses before and after LTP induction (black arrow). LTP was induced by 
pairing presynaptic 3 Hz stimulation (540 pulses) with postsynaptic depolarization (0 
mV), in control (uninfected) CA1 neurons (white symbols) and in PH-GRP1-expressing 
cells (black symbols). “n” represents number of cells. B. Quantification of average 
synaptic potentiation (“LTP Pathway”) from the last 5 min of the time course shown in A. 
One of the stimulating electrodes was turned off during LTP induction (“Unpaired 
Pathway”). Statistical significance was calculated with the Mann-Whitney test. “n” 
represents number of cells. C. CA1 neurons were transfected with different 
combinations of GluA2(R607Q) or GluA1 plus constitutively active CaMKII (tCaMKII), 
together with RFP or RFP-PH-GRP1 coexpression, as indicated. Synaptic responses 
were evoked at -60 mV and +40 mV to quantify inward rectification. The rectification 
index is calculated as the ratio of the amplitude of the synaptic response at -60 mV 
versus +40 mV. Rectification indexes were normalized to the average value obtained 
from untransfected cells (2.0 ± 0.3). “n” represents number of cells. Statistical 
significance was calculated according to the Mann-Whitney test. Representative traces 
of the recordings are plotted above their respective columns in the graph (scale bars: 20 
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pA, 10 ms). D. Similar experiments were carried out with CA1 neurons transfected with 
the indicated recombinant proteins and treated with 10 µM LY294002 or DMSO (vehicle 
control) for 1 hour (LY294002 and DMSO were also present during the recordings). 
Rectification index for uninfected, DMSO-treated cell was 2.4 ± 0.2. “n” represents 
number of cells. Statistical significance was calculated according to the Mann-Whitney 
test. Representative traces of the recordings are plotted above their respective columns 
in the graph (scale bars: 20 pA, 10 ms). 
 
Figure 5. Depletion of PIP3 leads to the accumulation of AMPA receptors in 
dendritic spines. A. Representative confocal images of total receptor (“GFP”, green) 
and surface anti-GFP labeling (“Cy5”, purple) in dendritic spines from neurons 
expressing GluA2-GFP with RFP (top panels) or with RFP-PH-GRP1 (bottom panels). 
B. Quantification of fluorescence intensity at spines versus the adjacent dendritic shaft 
from neurons as those shown in A. “Total Receptor” (left) is quantified from GFP 
fluorescence, and “Surface Receptor” (right) from Cy5 signal. Values of spine/dendrite 
ratios are normalized to the control (RFP-expressing neurons). The actual (non-
normalized) ratios for the control were (average ± s.e.m.): 1.15 ± 0.2 (total) and 1.0 ± 
0.1 (surface). “n” represents number of spines from 11 (GluA2 + RFP) or 25 (GluA2 + 
PH-GRP1) different neurons. Statistical significance was calculated according to t test. 
C. Neurons expressing GluA2-GFP were treated with 10 µM LY294002 or DMSO 
(vehicle control) for 1 hour prior to fixation and imaging. Total and surface receptors are 
plotted as in B. Values of spine/dendrite ratios are normalized to the control (DMSO-
treated neurons). The actual (non-normalized) values for the control were (average ± 
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s.e.m.): 1.5 ± 0.1 (total), 1.1 ± 0.2 (surface). “n” represents number of spines from 25 
(DMSO) or 22 (LY294002) different neurons. Statistical significance was calculated 
according to t test. 
 
Figure 6. Depletion of PIP3 impairs PSD-95 accumulation in spines and increases 
surface mobility of GluA2 recombinant receptors. A. Representative confocal 
images of dendritic spines from neurons expressing PSD-95-GFP (green images) with 
RFP (top panels) or with RFP-PH-GRP1 (bottom panels). B. Quantification of 
fluorescence intensity at spines versus the adjacent dendritic shaft from neurons as 
those shown in A. “n” represents number of spines from 29 (PSD-95 + RFP) or 12 
(PSD-95 + PH-GRP1) different neurons. Statistical significance was calculated 
according to t test. C. Cumulative distribution of spine/dendrite ratios from the same 
data plotted in B. Statistical significance is calculated according to the Kolmogorov-
Smirnov test. D. Examples of spines expressing GFP-GluA2, treated with either DMSO 
(vehicle) or 10 µM LY49002 for 1 hour prior to undergoing a FRAP experiment. 
Representative images are shown before photobleaching (“Baseline”), right after 
photobleaching (“Bleach”) and at different times during fluorescence recovery, as 
indicated. Bleached regions are indicated with dashed circles in the “Baseline” panels. 
E. Quantification of the amount of GluA2-GFP fluorescence at the spine normalized to 
the baseline value before photobleaching. Fluorescence intensity at the spine is 
normalized to the adjacent dendrite (spine/dendrite ratio) to compensate for ongoing 
photobleaching during image acquisition. Time courses obtained from DMSO- (white 
symbols) or LY294002-treated slices (black symbols) were fitted to single exponentials 
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(solid lines). Best-fit parameters were: τ=5.7 min, amplitude=0.26 (DMSO); τ=5.9 min, 
amplitude=0.52 (LY294002). Correlation coefficients were 0.71 (DMSO) and 0.84 
(LY294002). 
 
Figure 7. Depletion of PIP3 causes a redistribution of AMPARs between the PSD 
and extrasynaptic membrane. A. Examples of electron micrographs from CA1 
excitatory synapses labeled with anti-GluA2 immunogold (arrows). The presynaptic 
terminal is indicated with an asterisk. Slices were treated with either DMSO (vehicle) or 
10 µM LY294002 for 1 hour before fixation. Scale bars represent 100 nm. B. 
Quantification of GluA2 immunogold abundance at the PSD, the extrasynaptic 
membrane (“Extra”) or the intracellular space (“Intra”) from slices treated with DMSO 
(grey columns) or LY294002 (black columns). The number of gold particles at each 
compartment for a given synapse was divided by the total number of gold particles in 
that synapse. Average values ± s.e.m. are plotted for each compartment. “n” represents 
number of synapses analyzed. Statistical significance is calculated according to the 
Mann-Whitney test. C. Frequency histogram of the lateral distribution of GluA2 
immunogold particles contained within the PSD or the extrasynaptic membrane. Lateral 
distances are calculated for individual gold particles with respect to the closest PSD 
edge, with negative distances for particles within the PSD and positive distances for 
particles within the extrasynaptic membrane. Values are plotted for DMSO- (grey) and 
LY294002-treated slices (black). “n” represents number of gold particles. Statistical 
significance was calculated with a χ2 test (contingency table). D. The same values 
shown in C are plotted as cumulative distributions. “n” represents number of gold 
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particles. Statistical significance is calculated according to the Kolmogorov-Smirnov 
test. 
 
Figure 8. Inhibition of glutamate reuptake abolishes PH-GRP1-induced 
depression of AMPA receptor-mediated transmission. A. Comparison of evoked 
AMPAR responses from pairs of neighboring CA1 neurons expressing PH-GRP1 and 
control (uninfected) neurons after treatment with 100 µM L-trans-pyrrolidine-2,4-
dicarboxylate (L-t-PDC). L-t-PDC was added to the slice cultures 30 min before starting 
the recordings, and was also present during the recordings. “n” represents number of 
cell pairs. Statistical significance was calculated according to the Wilcoxon text. Inset. 
Example traces from uninfected and infected neurons. B. Time course of AMPAR-
mediated EPSCs from hippocampal CA1 neurons expressing PH-GRP1 (black 
symbols) or from control uninfected neurons (white symbols), in response to the 
addition of 100 µM L-t-PDC (indicated with an arrow). Values are normalized to the 
average EPSC amplitude before drug application. “n” represents number of cells. 
Statistical significance for the comparison between uninfected and PH-GRP1-
expressing neurons was done according to the Mann-Whitney test. Inset. 
Representative traces from a pair of uninfected and PH-GRP1-expressing neurons 
recorded simultaneously during drug application. Thin lines: average response before L-
t-PDC application. Thick lines: average response from the last 5 min of the time course. 
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METHODS 
Materials 
 The PI3K inhibitors LY294002 and wortmannin, and the glutamate uptake 
inhibitor L-Trans-pyrrolidine-2,4-dicarboxylate (L-t-PDC) were from Sigma. The 
antibodies used in this study were: anti-GFP (Roche); GluR2, GluR3, phospho-Akt 
(Thr308) and stargazin (Millipore); Akt (Cell Signaling); TARP γ-8 (Frontier Science, 
Hokkaido, Japan). 
 
Construction of recombinant proteins and expression 
The coding sequence of the pleckstrin homology (PH) domain of GRP1 was 
amplified by RT-PCR from rat brain mRNA and cloned downstream of the enhanced 
GFP (Clontech) (EGFP-PH-GRP1) or the red fluorescence protein variant tdimer248 
(RFP-PH-GRP1). The corresponding point mutant abolishing PIP3 binding, R284C23, 
was introduced by PCR-directed mutagenesis. The PH domain of human phospholipase 
C-δ1 fused to EGFP was obtained from Dr. Ronald Holz (PH-PLC-EGFP). A 
constitutively active form of PI3K was generated by adding an N-terminal myristoylation 
sequence to the catalytic domain (p110α) of mouse PI3K, as previously described24. 
This construct was then tagged with enhanced GFP (Clontech) at the C-terminus (Myr-
p110-EGFP). The EGFP-tagged AMPAR subunits (GluA1-EGFP and GluA2-R607Q-
EGFP), PSD-95 and the truncated αCaMKII construct (tCaMKII) were prepared as 
previously described31,49. The membrane-anchored form of GFP was obtained from 
Carlos Dotti. In this construct, the EGFP coding sequence is followed by a 21-aa 
farnesylation signal from H-Ras (pEGFP-CAAX). The pH-sensitive Super-Ecliptic-
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pHluorin-GluA2 construct was obtained from Roberto Malinow36. All these constructs 
were recloned in pSinRep5 for expression using Sindbis virus. Organotypic cultures of 
hippocampal slices were prepared from postnatal day 5-6 rats. After 4-5 days in culture, 
the recombinant gene is delivered into the slices using Sindbis virus or biolistic gene 
deliver (“gene gun”). Protein expression was typically for 15 h or for 1.5 days when 
expressing AMPAR subunits. All biosafety procedures and animal care protocols were 
approved by the University of Michigan Committee on Use and Care of Animals and the 
bioethics committee from the Consejo Superior de Investigaciones Cientificas (CSIC). 
 
Protein extracts and immunoprecipitations 
Protein extracts from hippocampal slices were prepared in 10 mM HEPES, 150 
mM NaCl, 10 mM EDTA, 0.1 mM phenylmethanesulphonylfluoride (PMSF), 2 μg/ml of 
chymostatin, leupeptin, antipain and pepstatin, and 1 % Triton X-100. For 
immunoprecipitations, 200-300 μg of protein extracts were incubated with 5 µg of the 
corresponding antibody and with 40 μl of protein G-sepharose beads (50%) (Amersham 
Biosciences), for 4 hours at 4°C. Samples were then washed and immunoprecipitated 
proteins were eluted by boiling in 1x Laemmli sample buffer and separated by SDS-
PAGE. Visualization of immunoprecipitated proteins was done by Western Blot and 
chemiluminescence. 
 
In vitro phosphoinositide binding assays 
PIP pull-down assay. Different PH-domain EGFP fusion proteins were expressed in 
organotypic hippocampal slice cultures using the Sindbis virus. Slices were then 
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homogenized in a buffer containing 10 mM HEPES pH 7.4, 150 mM NaCl, 0.5% 
Nonidet P-40, 5 mM DTT, 0.1 mM PMSF, 10 µg/µL chymostatin, 10 µg/µL leupeptin, 10 
µg/µL antipain, 10 µg/µL pepstatin. Insoluble extracts were removed via high-speed 
centrifugation (1 min, 13,200 rpm). The supernatants are then incubated for 3 hours at 4 
ºC with PI(4,5)P2- or PI(3,4,5)P3-coated agarose beads, or with control, uncoated beads 
(Echelon). Bound and unbound fractions are then separated by centrifugation (pull-
down). The presence of the different PH domains in the bound fractions was tested by 
western blot using anti-GFP antibodies. 
PIP membrane overlay assay. Different PH domains fused to EGFP were expressed in 
BHK cells via Sindbis virus. Whole-cell extracts are then prepared in 1% non-fat dry milk 
dissolved in PBS with 0.1% Tween-20. Insoluble material is removed by centrifugation. 
Protein extracts are applied on phosphoinositide strips (Echelon) and incubated for 2 
hours at room temperature. The phosphoinositide strips are then washed with PBS-
Tween and incubated with anti-GFP for detection of bound recombinant proteins. 
 
Electrophysiology 
Voltage-clamp simultaneous whole-cell recordings are obtained from nearby 
pairs of infected and uninfected (control) CA1 pyramidal neurons, under visual guidance 
using fluorescence and transmitted light illumination. The recording chamber is perfused 
with 119 mM NaCl, 2.5 mM KCl, 4 mM CaCl2, 4 mM MgCl2, 26 mM NaHCO3, 1 mM 
NaH2PO4, 11 mM glucose, 0.1 mM picrotoxin, and 4 μM 2-chloroadenosine, at pH 7.4, 
gassed with 5% CO2/95% O2. Patch recording pipettes (3–6 MΩ) are filled with 115 mM 
cesium methanesulfonate, 20 mM CsCl, 10 mM HEPES, 2.5 mM MgCl2, 4 mM Na2ATP, 
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0.4 mM Na3GTP, 10 mM sodium phosphocreatine, and 0.6 mM EGTA at pH 7.25. 
Synaptic responses are evoked with bipolar electrodes using single-voltage pulses (200 
μs, up to 20 V). The stimulating electrodes are placed over Schaffer collateral fibers 
between 300 and 500 μm from the recorded cells. Because only CA1 cells (and not CA3 
cells) are infected, this configuration ensures that recombinant proteins are always 
expressed exclusively in the postsynaptic cell. Synaptic AMPAR-mediated responses 
are measured at −60 mV and NMDA receptor (NMDAR)-mediated responses at +40 
mV, at a latency when AMPAR responses have fully decayed (60 ms). For rectification 
studies, AMPAR responses were recorded at -60 mV and +40 mV in the presence of 
0.1 mM D,L-2-amino-5-phosphonovaleric acid (APV) in the perfusion solution and 0.1 
mM spermine in the intracellular solution. Synaptic responses are averaged over 50–
100 trials. LTP was induced using a pairing protocol by stimulating Schaffer collateral 
fibers at 3 Hz (540 pulses) while depolarizing the postsynaptic cell to 0 mV. Field 
excitatory postsynaptic potentials (fEPSPs) were acquired with 2.5 M NaCl in the 
recording pipette. All electrophysiological recordings were carried out with Multiclamp 
700A/B amplifiers (Axon Instruments). 
 
Confocal fluorescence imaging 
Fluorescence images were acquired with an Olympus FV500 confocal 
microscope and a 63x lens using FluoView software. Surface immunostaining for 
EGFP-tagged AMPAR subunits was carried out under nonpermeabilized conditions 
using anti-GFP (Roche) and biotinylated anti-mouse (Sigma) antibodies, and 
streptavidin coupled to Cy5 (Amersham Biosciences) (detergents were omitted in all 
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incubations). Image analysis was carried out with Image J. Briefly, line plots of 
fluorescence intensity were generated across spine heads and the adjacent dendritic 
shafts. Fluorescence intensity at each compartment was quantified from the peaks 
corresponding to the spine and the dendrite after background subtraction. 
Spine/dendrite ratios were calculated from these values. This method is internally 
normalized for immunostaining variability, since immunofluorescence values are always 
acquired in pairs of spine and adjacent dendrite. Additionally, spine-dendrite pairs are 
always selected from the GFP channel, avoiding any bias with respect to their surface 
immunostaining. 
For fluorescence recovery after photobleaching (FRAP) experiments, GFP signal 
from dendritic spines or specific dendritic regions was photobleached with high laser 
intensity for 5 seconds. Recovery of fluorescence was measured at different time 
intervals after photobleaching. Fluorescence values at the bleached area are 
normalized to those at an adjacent “non-bleached” region, to compensate for ongoing 
bleaching during imaging. 
 
Postembedding immunogold 
Hippocampal slices were fixed and processed for osmium-free post-embedding 
immunogold labeling essentially as described previously50. AMPARs were labeled with 
anti-GluA2 or -GluA3 antibodies (Millipore), and secondary antibodies coupled to 10-nm 
gold particles (Electron Microscopy Sciences). Electron micrographs were obtained with 
a Philips CM-100 transmission electron microscope and a Kodak 1.6 Megaplus digital 
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camera. Quantification of gold particles and distance measurements were performed on 
the digital images using Image J software. 
 
Statistical analyses 
All graphs represent average values ± s.e.m. Statistical differences were calculated 
according to nonparametric tests. Comparisons between multiple groups were 
performed with the Kruskal-Wallis ANOVA. When significant differences were observed, 
p values for pairwise comparisons were calculated according to two-tailed Mann-
Whitney tests (for unpaired data) or Wilcoxon tests (for paired data). Comparisons 
between cumulative distributions (Figs. 6C, 7D and Supplementary Fig. 9C) were 
performed according to two-sample Kolmogorov–Smirnov tests. p values are indicated 
in each figure. 
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1SUPPLEMENTARY INFORMATION
Supplementary Figure 1. Alteration of PIP3 does not alter passive membrane 
properties of CA1 pyramidal neurons. Expression of PH-GRP1 (A), PH-GRP1-
R284C (B) or Myr-p110 (C) does not alter input resistance, holding current or cell 
capacitance of infected CA1 pyramidal neurons (black columns) compared to uninfected 
cells (white columns). 
Supplementary Figure 2. Expression of Myr-p110-EGFP and alterations in Akt 
phosphorylation. A. Expression of Myr-p110-EGFP in a CA1 pyramidal neuron. Myr-
p110-EGFP is widely distributed throughout dendrites and spines (inset). B. Expression 
of Myr-p110-EGFP in CA1 neurons increases the phosphorylation of Akt at Thr308 site 
compared to GFP infection. Slices infected with GFP then treated with 10 M LY294002 
for 1 hour show decreased phosphorylation of Akt compared to GFP control. 
Supplementary Figure 3. Surface immunostaining of AMPA receptors under non-
permeabilized conditions. Hippocampal slices were infected with GluA2-GFP (A) or 
cytosolic EGFP (B) and processed for immunostaining under permeabilizing (“+Triton”, 
lower panels) or non-permeabilizing (“-Triton”, upper panels) conditions. Total 
expression of the recombinant protein is detected from its green fluorescence (“GFP” 
panels). “Cy5” panels reflect immunostaining with an anti-GFP antibody and a 
secondary antibody coupled to Cy5. Under non-permeabilizing conditions, GluA2-GFP 
2is only detected in the periphery of the cell (possibly the cell surface). Cytosolic GFP is 
not detectable under these conditions. 
Supplementary Figure 4. Depletion of PIP3 does not alter long-range dendritic 
trafficking of AMPA receptors in CA1 neurons. A. Representative examples of CA1 
hippocampal neurons expressing GluA2-GFP (green images) together with RFP or 
RFP-PH-GRP1 (red images), as indicated. B. Fluorescence intensity of GluA2-GFP 
along the primary apical dendrite was quantified from neurons as those shown in A 
(GluA2-GFP + RFP: black; GluA2-GFP + RFP-PH-GRP1: red). Values are normalized 
to the GFP fluorescence at the cell soma. Averages are plotted with thick lines and 
s.e.m. with thin lines above and below the corresponding average. “n” represents 
number of cells analyzed. 
Supplementary Figure 5. PIP3 depletion does not alter spine size nor the 
distribution of PH-PLC (PIP2 reporter). A. Quantification of spine size from DMSO- or 
LY294002-treated CA1 hippocampal neurons expressing cytosolic EGFP as a volume-
filling indicator. Spine size is estimated as the ratio of EGFP fluorescence at the spine 
versus the dendrite. Two representative spines for each condition are shown above the 
quantification. “n” represents number of spines from 24 (DMSO) or 26 (LY294002) 
different neurons. B. Quantification of PIP2 distribution from spine/dendrite ratios of 
GFP-PH-PLC in the presence of RFP or RFP-PH-GRP1. Representative images of 
dendritic spines expressing PH-PLC-GFP (green images) together with RFP (left) or 
3RFP-PH-GRP1 (right) (red images) are shown above the quantification. “n” represents 
number of spines from 18 (RFP) or 19 (PH-GRP1) different neurons. 
Supplementary Figure 6. The mobility of membrane-anchored GFP is not altered 
by LY294002. A. Representative images of cell bodies (left panel) and dendritic 
branches (right panel) from neurons expressing farnesylated GFP (GFP-CAAX; see 
Methods). B. Examples of spines expressing GFP-CAAX, treated with either DMSO 
(vehicle) or 10 µM LY294002 for 1 hour prior to undergoing a FRAP experiment (DMSO 
or LY294002 are also present in the perfusion solution during imaging). Representative 
images are shown before photobleaching (“Baseline”), immediatly after photobleaching 
(“Bleach”) and at different times during fluorescence recovery, as indicated. C.
Quantification of the amount of GFP fluorescence at the spine normalized to the 
baseline value before photobleaching. Fluorescence intensity at the spine is normalized 
to the adjacent dendrite (spine/dendrite ratio) to compensate for ongoing 
photobleaching during image acquisition. “n” represents number of spines. 
Supplementary Figure 7. The mobility of dendritic AMPARs is not altered by 
LY294002. A. Representative examples of dendritic branches expressing GFP-GluA2, 
treated with either DMSO (vehicle) or 10 µM LY294002 for 2 hours prior to undergoing a 
FRAP experiment (DMSO or LY294002 are also present in the perfusion solution during 
imaging). Representative images are shown before photobleaching (“Baseline”), 
immediately after photobleaching (“Bleach”) and at different times during fluorescence 
recovery, as indicated. The section of the dendrite undergoing bleaching is indicated 
4with a dashed white rectangle. B. Quantification of the amount of fluorescence recovery 
from images similar to those in A. GFP fluorescence intensity at the bleached area is 
normalized to the baseline value before photobleaching. Fluorescence intensity at the 
bleached area is also is normalized to an adjacent “non-bleached” region of the dendrite 
to compensate for ongoing photobleaching during image acquisition. “n” represents 
number of dendritic branches from different neurons. Grey and black lines correspond 
to the exponential best fits to the experimental data from DMSO- and LY294002-treated 
slices, respectively.
Supplementary Figure 8. Inhibition of PIP3 synthesis does not impair PSD-
95/TARP interaction. Hippocampal slices were treated with 10 µM LY-294002 for 2 
hours (“LY”) or left untreated (“”). Total protein extracts were then immunoprecipitated 
with anti-8, anti-2 (stargazin) or a non-immune antibody (n.i.), as indicated. 
Immunoprecipitated proteins were visualized with anti-PSD-95 (A), 8 (B) or 2 (C).
10% of the input extracts are shown in the left panels. Bands from the 
immunoprecipitating antibodies are indicated with arrows (IgG). 
Supplementary Figure 9. GluA3 distributes to the perisynaptic membrane after 
treatment with LY294002. A. Examples of electron micrographs from CA1 excitatory 
synapses labeled with anti-GluA3 immunogold (arrows). The presynaptic terminal is 
indicated with an asterisk. Slices were treated with either DMSO (vehicle) or 10 µM 
LY294002 for 1 hour before fixation. Scale bars represent 100 nm. B. Quantification of 
GluA3 immunogold abundance at the PSD or the extrasynaptic membrane (“Extra”) of 
5the spine from slices treated with DMSO (grey columns) or LY294002 (black columns). 
The number of gold particles at each compartment for a given synapse was divided by 
the total number of gold particles in that synapse. Average values ± s.e.m. are plotted 
for each compartment. “n” represents number of synapses analyzed. Statistical 
significance is calculated according to the Mann-Whitney test. C. Cumulative frequency 
distribution of the lateral distribution of GluA3 immunogold particles contained within the 
PSD or the extrasynaptic membrane. Lateral distances are calculated for individual gold 
particles with respect to the closest PSD edge, with negative distances for particles 
within the PSD and positive distances for particles within the extrasynaptic membrane. 
Values are plotted for DMSO- (grey) and LY294002-treated slices (black). “n” 
represents number of gold particles. Statistical significance is calculated according to 
the Kolmogorov-Smirnov test. 
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